Trials / Completed
CompletedNCT05055947
Efficacy Biomarker Investigation on Extensive Stage Small Cell Lung Cancer
Efficacy Biomarker Investigation on Extensive Stage Small Cell Lung Cancer Who Treated With Atezolizumab Plus Etoposide and Platinum Based Chemotherapy
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 60 (actual)
- Sponsor
- Hunan Province Tumor Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the trial is to find some biomarkers to predict the efficacy of Atezolizumab plus etoposide and platinum based chemotherapy as the first line treatment in extensive stage small cell lung cancer. Mainly observe the patient's progression free survival time after treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | First line EC/EP+Atezolizumab | Etoposide (100mg/㎡) Carboplatin (AUC=4) Atezolizumab(1200mg) ivgtt, every 21 days |
Timeline
- Start date
- 2019-04-01
- Primary completion
- 2021-07-01
- Completion
- 2021-09-14
- First posted
- 2021-09-24
- Last updated
- 2022-01-25
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05055947. Inclusion in this directory is not an endorsement.